Literature DB >> 19271113

High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population.

Tomomi Kogiso1, Yuriko Moriyoshi, Satoru Shimizu, Hikaru Nagahara, Keiko Shiratori.   

Abstract

BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) has been developed and used as a marker to predict coronary vascular diseases in metabolic syndrome (MS). We investigated whether serum hs-CRP concentration was associated with nonalcoholic fatty liver disease (NAFLD) based on the Akaike Information Criterion (AIC) scoring system, using patients from the human dry dock program.
METHODS: From 2004 to 2005, 1254 subjects visited our human dry dock annual checkup program. We excluded from this study individuals with markers of viral hepatitis and those whose alcohol consumption was more than 20 g/week. Finally, 230 subjects (93 men and 137 women) were investigated. Serum hs-CRP concentrations were measured using a highly sensitive latex agglutination assay system. The AIC scoring system with the CATDAP-20 program was introduced to evaluate the parameters that are present frequently in NAFLD.
RESULTS: NAFLD was diagnosed by ultrasound sonography in 35.4% of the men and 18.9% of the women. High serum hs-CRP concentrations were observed in women with NAFLD (normal: NAFLD = 0.45:1.47 mg/l, P < 0.05). Body mass index (BMI), waist circumference, and body weight had the three lowest AIC score (P = 4.5e(-19) to 2.6e(-16)). hs-CRP was the third lowest variable among the serum markers associated with NAFLD (P = 2.3e(-6)) In addition, the hs-CRP concentration was correlated strongly with triglyceride values in females with NAFLD and with fasting blood glucose, HbA1c, and waist/hip ratio in males with NAFLD (P < 0.05).
CONCLUSIONS: The serum hs-CRP concentration was a strong predictor for NAFLD with a low AIC score and correlated with serum markers that indicated lipid and glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19271113     DOI: 10.1007/s00535-009-0002-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  38 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes.

Authors:  Eun Seok Kang; Hyeong Jin Kim; Chul Woo Ahn; Cheol Won Park; Bong Soo Cha; Sung Kil Lim; Kyung Rae Kim; Hyun Chul Lee
Journal:  Diabetes Res Clin Pract       Date:  2005-01-12       Impact factor: 5.602

4.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

Review 5.  Should nonalcoholic fatty liver disease be renamed?

Authors:  Paola Loria; Amedeo Lonardo; Nicola Carulli
Journal:  Dig Dis       Date:  2005       Impact factor: 2.404

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 7.  Abdominal obesity and metabolic syndrome.

Authors:  Jean-Pierre Després; Isabelle Lemieux
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

8.  Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome.

Authors:  A-C Santos; C Lopes; J T Guimarães; H Barros
Journal:  Int J Obes (Lond)       Date:  2005-12       Impact factor: 5.095

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.

Authors:  Seung Ha Park; Byung Ik Kim; Jung Won Yun; Jeong Wook Kim; Dong Il Park; Yong Kyun Cho; In Kyung Sung; Chang Young Park; Chong Il Sohn; Woo Kyu Jeon; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim
Journal:  J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 4.029

View more
  23 in total

1.  The relationship between arterial stiffness and nonalcoholic fatty liver disease.

Authors:  Yong-Jae Lee; Jae-Yong Shim; Byung-Soo Moon; Youn-Ho Shin; Dong-Hyuk Jung; Jung-Hyun Lee; Hye-Ree Lee
Journal:  Dig Dis Sci       Date:  2011-07-13       Impact factor: 3.199

Review 2.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 3.  Chronic liver inflammation: clinical implications beyond alcoholic liver disease.

Authors:  Byoung-Jin Park; Yong-Jae Lee; Hye-Ree Lee
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population.

Authors:  Xin-yan Yu; Yi Zhao; Xiao-xiao Song; Zhen-ya Song
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

5.  C-reactive protein does not impair insulin suppression of glucose release in primary hepatocytes.

Authors:  F Ellis; A Nivala; K T Pfaffenbach; C L Gentile; D Wang; Y Wei; M J Pagliassotti
Journal:  Nutr Metab Cardiovasc Dis       Date:  2010-08-05       Impact factor: 4.222

6.  Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.

Authors:  Chung-Feng Huang; Ming-Yen Hsieh; Jeng-Fu Yang; Wu-Cheng Chen; Ming-Lun Yeh; Ching-I Huang; Chia-Yen Dai; Ming-Lung Yu; Zu-Yau Lin; Shinn-Chern Chen; Wan-Long Chuang; Jee-Fu Huang
Journal:  Hepatol Int       Date:  2010-08-04       Impact factor: 6.047

7.  Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults.

Authors:  S H Lee; J M Yun; S H Kim; Y G Seo; H Min; E Chung; Y S Bae; I S Ryou; B Cho
Journal:  J Endocrinol Invest       Date:  2016-08-25       Impact factor: 4.256

8.  Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans.

Authors:  Charmaine S Tam; Alexander Viardot; Karine Clément; Joan Tordjman; Katherine Tonks; Jerry R Greenfield; Lesley V Campbell; Dorit Samocha-Bonet; Leonie K Heilbronn
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

9.  Adiponectin and IL-6: Mediators of inflammation in progression of healthy to type 2 diabetes in Indian population.

Authors:  Smitha Upadhyaya; Vinitha Kadamkode; Rafi Mahammed; Chandraprabha Doraiswami; Gautam Banerjee
Journal:  Adipocyte       Date:  2013-10-08       Impact factor: 4.534

10.  The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease.

Authors:  Tugrul Purnak; Yavuz Beyazit; Ersan Ozaslan; Cumali Efe; Merve Hayretci
Journal:  Wien Klin Wochenschr       Date:  2012-08-01       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.